Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD Patients
Pulmonary Disease, Chronic Obstructive
Drug: Tiotropium bromide
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||A Randomized, Double Blind , Placebo Controlled Trial to Compare the Effect of Tiotropium Inhalation Capsules on Exercise Tolerance in Patients With COPD Participating in 8 Weeks of Pulmonary Rehabilitation|
- Change in six minute walk distance after 8 weeks of pulmonary rehabilitation. [ Time Frame: week 13 ] [ Designated as safety issue: No ]
- Individual FEV1 measurement [ Time Frame: week 4, 13, 25 ] [ Designated as safety issue: No ]
- Individual FVC measurement [ Time Frame: week 4, 13, 25 ] [ Designated as safety issue: No ]
- St. George's Hospital Respiratory Questionnaire (SGRQ) [ Time Frame: Time Frame: week 4, 13, 25 ] [ Designated as safety issue: No ]
- Transition dyspnea index [ Time Frame: week 4, 13, 25 ] [ Designated as safety issue: No ]
- COPD symptom scores (wheezing, shortness of breath, coughing and tightness of chest [ Time Frame: week 4, 13, 25 ] [ Designated as safety issue: No ]
- Amount of salbutamol therapy used during the treatment period [ Time Frame: 25 weeks ] [ Designated as safety issue: No ]
- Number and length of exacerbations of COPD [ Time Frame: 25 weeks ] [ Designated as safety issue: No ]
- Physician's global evaluation [ Time Frame: week 4, 13, 25 ] [ Designated as safety issue: No ]
- Patient peak flow rates (PEFR) twice daily [ Time Frame: 25 weeks ] [ Designated as safety issue: No ]
- Patient activity measurement [ Time Frame: week 4, 9, 13, 17, 21, 25 ] [ Designated as safety issue: No ]
- Six minute walk distance [ Time Frame: week 13, 25 ] [ Designated as safety issue: No ]
- Occurrence of adverse events [ Time Frame: 25 weeks ] [ Designated as safety issue: No ]
- Changes from baseline in Pulse rate and blood pressure in conjunction with spirometry [ Time Frame: 25 weeks ] [ Designated as safety issue: No ]
- Changes in the physical examination from baseline and at the conclusion of patient participation in the trial [ Time Frame: 25 weeks ] [ Designated as safety issue: No ]
|Study Start Date:||September 2002|
|Study Completion Date:||April 2006|
|Primary Completion Date:||April 2006 (Final data collection date for primary outcome measure)|
This is an 25-week multicenter, single country, randomised, double-blind, placebo-controlled, parallel group study to compare the efficacy of tiotropium inhalation capsules (Spiriva, Bromuro de Tiotropio) in patients with COPD participating in a pulmonary rehabilitation program.
Following an initial screening, patients will perform a six minute walk test (Visit 1) and enter a 4-week run-in period. Patients will subsequently be randomized to tiotropium or placebo inhalation capsules taken once daily in the morning for the next 25 weeks. After successfully completing 4 weeks of study drug self-administration, patients will enter a period of pulmonary rehabilitation.
Pulmonary rehabilitation will include aerobic lower limb exercise 3 times weekly for 8 weeks. After the last pulmonary rehabilitation session, patients will continue on study medication for a 12 week follow-up period.
Six minute walk tests will be repeated during the run-in period at Week 0 (Visit 2) and Week 4 (Visit 3), at the conclusion of the 8 weeks of pulmonary rehabilitation (Visit 6) and the 12 weeks of follow-up (Visit 9).
Pulmonary function testing will be conducted prior to the start of therapy at Visit 1 and at Visits 2 (week 0 ), 3 (week 4 ), 6 (week 13 ) and 9 (week 25 ).
The null hypothesis is that there is no difference in the increase in six minute walk distance between tiotropium and placebo groups following 8 weeks pulmonary rehabilitation program. The alternative hypothesis is that tiotropium with pulmonary rehabilitation increases six minute walk distance more than placebo with pulmonary rehabilitation. However, the two-sided test of hypothesis will be performed at 0.05 level of significance.
The primary endpoint is the six minute walk distance at visit 6. This endpoint will be compared between tiotropium and placebo using an analysis of covariance model with treatment, center and baseline (six-minute walk distance measured at visit 2 prior to dosing) as a covariate. Fifty-four meters has been determined to be the difference in six minute walk distance between tiotropium (Spiriva, Bromuro de Tiotropio) and placebo at 5% level of significance with at least 80% power using a two-tailed t-test.. .
Please refer to this study by its ClinicalTrials.gov identifier: NCT00157235
|Fondazione "S. Maugeri"|
|Bari, Italy, 70020|
|Azienda Sanitaria Locale|
|Casorate Primo (PV), Italy, 27022|
|Arcispedale S. Anna|
|Ferrara, Italy, 44100|
|U.O. dimedicina Preventiva del Lavoro|
|Genova, Italy, 16132|
|Gussago (BS), Italy, 25064|
|Universita degli Studi di Pisa|
|Pisa, Italy, 56124|
|Fondazione Don Gnocchi|
|Pozzolatico (fi), Italy, 50020|
|Azienda Ospedaliera S. Camillo Forlanini|
|Roma, Italy, 00149|
|Fondazione S. Maugeri|
|Telese Terme (BN), Italy, 82037|
|Fondazione "S. Maugeri"|
|Tradate (VA), Italy, 21049|
|Ospedali Riuniti di Trieste|
|Trieste, Italy, 34100|
|Casa di Cura San Raffaele|
|Velletri (Roma), Italy, 00049|
|Study Chair:||Boehringer Ingelheim Study Coordinator||BI Italy|